Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

The venture capital firm Atlas Venture is launching a start-up that aims to develop antisense oligonucleotides for a ...

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.

Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company's launch and $100 million in initial financing, including seed financing and ...

In a report released today, Maury Raycroft from Jefferies maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report), ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price ...

Global Lipid Nanoparticles Market was valued at US$ 820.51 million in 2023 and is projected to hit the market valuation of US$ 2,387.98 million by 2032 at a CAGR of 12.6% during the forecast period ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Protesters worldwide demand end to Israel’s year of war on Gaza Protesters have marched this weekend in cities around the world to demand an end to Israel’s brutal war on Gaza.